# BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT05393466** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Xcovery Holdings, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Non-small Cell Lung Carcinoma

## Interventions

- **DRUG:** BPI-361175

## Key facts

- **NCT ID:** NCT05393466
- **Lead sponsor:** Xcovery Holdings, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-01-30
- **Final completion:** 2029-05-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05393466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05393466, "BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05393466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*